Veracyte

Company profile

About Veracyte

Veracyte is a global genomic diagnostics company that develops and commercializes molecular tests to guide cancer care decisions. The company's high-performing molecular tests empower clinicians and their patients with important information that has helped guide care decisions for over 900,000 people across multiple cancer types. Veracyte's tests assess the unique biology of each patient's tumor to help clinicians answer key questions and make confident decisions for thyroid, prostate, breast, bladder, and lung cancer. The company's portfolio includes the Afirma Genomic Sequencing Classifier for thyroid nodules, Decipher tests for prostate and bladder cancer, Prosigna Breast Risk of Recurrence Test, and TrueMRD Monitoring Test for muscle-invasive bladder cancer. Veracyte's proprietary Diagnostics Platform performs whole-transcriptome profiling on every test sample, creating an ever-expanding database that powers new insights, generates robust clinical evidence, and enables new applications across the cancer care continuum. This integrated approach combines comprehensive genomic profiling, AI-powered analysis, rigorous clinical studies, and expanding test applications to deliver personalized and effective patient care. The platform has generated over 600 peer-reviewed publications and is supported by more than 35 Phase 2 and 3 clinical trials. Veracyte's tests are widely recommended in clinical guidelines, with Decipher Prostate being the only gene expression test included in the NCCN Clinical Practice Guidelines for prostate cancer.

Company description · Veracyte official website